Hide table of contents

I’m Alex Cohen, Principal Researcher at GiveWell. From time to time, we get questions from people outside of GiveWell about ways they could help our research. I decided to write down a few concrete research questions that I think would be informative to us and seem doable primarily with desk-based research, rather than original data collection or field visits (though those would probably help).

These are listed below. They’re not in any particular order and are roughly similar levels of priority. While our team may work on some of these questions over the next year, even in those cases, extra input is still likely to be useful.

If you decide to take these on, I’d be interested in what you find, so please post your answers to the forum. Also, if you find these types of questions interesting, please consider applying for our Senior Researcher role.

“Red teaming” some newer grantmaking areas

We recently published our findings from “red teaming” our top charities and previously did a Change Our Mind contest to find errors in our top charities and other programs where we’ve directed a lot of funding.

However, we’ve solicited less external scrutiny beyond these large grantmaking areas. Can you find errors in our published material on newer programs?

A few programs where we’ve made grants already and may consider providing more funding in the future are below:

  • Chlorination[1]

  • Malnutrition[2]

  • Syphilis screen and treat[3]

  • Kangaroo Mother Care (KMC)[4]

  • Tuberculosis contact management[5]

  • Participatory Learning and Action (PLA)[6]

You can see the type of questions that we ask during red teaming in this rough document.

Moral weights questions

We’ve spent a decent amount of time trying to understand the trade-offs between increases in consumption, averting deaths, and reducing morbidity via our moral weights, but there’s some desk-based work we haven’t done.

Two examples:

  • How do our estimates compare to recent estimates from value of a statistical life (VSL) studies in low- and middle-income countries specifically? If they’re different, how plausible do we think these differences are? We haven’t done a comprehensive review of this literature recently to understand how they compare to our moral weights, and it’s possible more work could lead to changes on how we trade off averting deaths for increased income, for example.[7]

  • Is there any evidence we could use to check our assumptions on averting morbidity vs. consumption? For example, we assume that averting a year of clubfoot is as valuable as increasing consumption by ~50% and that averting a year of severe anemia is as valuable as increasing income by ~60%.[8] Is there any evidence that exists that would help us discipline these estimates (either for these morbidities or others like fistula or cataracts)? How much are individuals in LMICs willing to trade off to avert morbidity?

Burden of disease questions

Our cost-effectiveness estimates rely heavily on data on burden of disease from the Institute for Health Metrics and Evaluation (IHME). However, we have some outstanding questions about these data.

We’ve noticed some cases where these data are out of sync with other sources. Our current approach is to consider putting weight on both. For example, in our report on red teaming our top charities, we note a couple examples:

  • All-cause mortality across Nigerian states. Our estimates of under-5 all-cause mortality rates in Nigerian states, which are a key driver of our decisions about where to fund New Incentives' conditional cash transfer program, rely heavily on data from the Institute for Health Metrics and Evaluation (IHME). However, we found that IHME's estimates are negatively correlated with estimates from the United Nations Interagency Group for Child-Mortality Estimation (UN IGME) across the states where New Incentives operates. If UN IGME estimates are more accurate, relying solely on IHME could lead us to fund New Incentives’ program in less cost-effective states.
    Additionally, the UN IGME’s estimates are, on average, 35-40% higher than IHME's estimates in states where New Incentives operated as of January 2024. If we come to believe that UN IGME’s results are more reliable, or it is best to take an average of the two, then relying on IHME alone is causing us to underestimate overall disease burden and, consequently, underestimate the potential impact of New Incentives' program.
  • Malaria mortality in Chad. Our estimates of the malaria burden in Chad are significantly lower than in other countries where we fund malaria interventions, but we have not thoroughly investigated the reasons for this discrepancy. A comparison of under-5 malaria mortality estimates from the UN IGME and IHME across several African countries reveals substantial variation. For example, the UN IGME estimate for under-5 malaria mortality in Chad is ~2.5 times higher than IHME's estimate, while in Guinea, the estimates are virtually the same, and in Uganda, the UN IGME estimate is only ~45% as high as IHME's. These inconsistencies raise questions about the reliability of the data we use to estimate the malaria burden and, consequently, the cost-effectiveness of malaria interventions in different countries.

We include some additional examples in our report on the optimizer’s curse and uncertainty in our grantmaking.

The broad question here is: How do IHME’s estimates of mortality and burden of disease compare to other sources?  Which source(s) should we put more stock in?

Some more specific questions:

  • The example above from Chad suggests we may have been undervaluing malaria programs in Chad. (We’ve since begun accounting for this in our grantmaking decisions.) Can you find other examples of our work where incorporating estimates from non-IHME sources might change our decisions?
  • IHME says the under 5 mortality rate in Uganda in 2021 was 6.5%, slightly higher than neighboring DRC (around 5.8%) and nearly twice as high as Kenya (3.7%).[9] IGME says it was 4.2% in both Uganda and Kenya, and nearly twice as high (7.8%) in DRC.[10] What estimate should we use?

  • Across 5 countries in Africa where we have supported or considered supporting campaigns to distribute insecticide-treated nets (DRC, Uganda, Chad, South Sudan, and Zambia), GBD’s estimates of the share of 1-59-month-old deaths due to malaria vary from 8% to 44%, while IGME’s estimates for all 5 countries are between 15% and 30%.[11] How much variation should we expect across countries? This is important for us. If the share of deaths due to malaria is similar across countries, then we mostly care about prioritizing areas with high all-cause mortality. If it’s more spread out, then we’d want to prioritize finding the most malarious regions.

  • IHME’s 2021 maternal mortality rate estimate in Nigeria is 299 per 100,000 live births. The WHO/UNICEF ("MMEIG") estimate is 1,047 per 100,000.[12] That is a huge difference and could materially affect whether programs focused on reducing maternal mortality would or wouldn't look cost-effective to us. Which source should we believe? What should our best guess be?

  • How many people over the age of 5 are dying of malaria, and how much does this vary across areas? Across states in Nigeria, the IHME estimates anywhere from 0.3 to 2.5 over-5 deaths per under-5 death.[13] Should we believe this variation reflects true differences across states?

Indirect deaths

In our recent report on red teaming our top charities, we write:

“Indirect deaths” are deaths that wouldn’t have occurred without the incidence of a disease, but aren’t directly attributable to that disease in disease burden data. For example, someone who had contracted malaria might die from an unrelated disease because malaria weakened their immune system. We account for the indirect deaths averted by a program by estimating how many indirect deaths are averted for every direct death averted. Our assumptions about indirect deaths vary significantly across programs, ranging from ~5 indirect deaths averted for each direct death averted for vitamin A supplementation (VAS), 0.75 for malaria and vaccines, and ~2 for water chlorination. We have not thoroughly assessed whether these magnitudes, or their relative sizes across top charities, are plausible.[14]

Is there research available that could help us pick the right values for these indirect deaths for different interventions? How does this research accord with our current work? Are there heuristics we should use for estimating indirect effects across different interventions or countries?

Some more specific questions:

  • We based this comparison partially on a comparison of all-cause mortality effects to cause-specific effects in randomized trials, but we haven’t done anything systematic.[15] For example, looking at the biggest meta-analyses, what's the typical relationship between cause-specific effects and all-cause effects? What should our best guess be based on those studies? How should we think about internal validity (e.g., publication bias) or external validity (e.g., whether indirect deaths should be lower today as new vaccines or other programs have come online)?

  • Is there anything we can learn from the literature on non-specific effects on vaccines specifically? Our impression is that there's a large literature here, but we’re not sure how reliable it is and how much guidance it could give us on this question.
  1. ^

     See our intervention page on water quality interventions, that focuses on chlorination programs, and overall water quality CEA here. We’ve made grants to several types of chlorination interventions including Evidence Action’s Dispensers for Safe Water (CEA) and in-line chlorination (CEA).

  2. ^

     See our intervention report on community-based management of acute malnutrition (CMAM) and CEA. We’ve made recent grants in malnutrition here, here, and here.

  3. ^

     See our interim intervention report on Syphilis Screening and Treatment During Pregnancy (CEA). We’ve also made several grants to Evidence Action’s syphilis program including this most recent grant, as of the time of this post.

  1. ^
  2. ^
  3. ^

     See our recent intervention report, preliminary CEA, and previous grant pages here and here.

  4. ^

     In our current page, we say:

    A further challenge is that there is little revealed preference or stated preference research conducted in LMICs; most VSL and similar analyses estimate how much people value life in LMICs by extrapolating from high-income country research.11 A key issue with extrapolation is that one needs to make an assumption about how much the relative value of income versus health changes when a population is much poorer (often referred to as "the elasticity of demand for health"). Perhaps someone who barely has enough money to survive would greatly prefer any increase in income more than an additional year of life. Different assumptions about how to extrapolate can lead to estimates of the value of a DALY that vary by at least an order of magnitude.12

    Though the literature on VSL in LMIC contexts is limited, we are aware of a few potentially relevant empirical papers on the topic, which are briefly summarized in León and Miguel 2016, itself an estimate of VSL in an LMIC context (see following footnote).13 These papers generally appear to find substantially lower values of health relative to income than are estimated in high-income countries.14 We have not yet carefully vetted these papers and expect to review them more closely in the future, but our impression is that estimates of the value of life from these papers have not yet been used by major decision makers and are based on different methodologies than typical VSL estimates, so they should not yet be interpreted as "standard" assumptions.15

    Because of limitations in the existing literature, we do not see current "best guess" estimates of the relative value of income versus health in LMICs as robust.

    Our current moral weights from here:

    • Value of doubling consumption for one person for one year: 1
    • Value of preventing one under-5 death from malaria: 116.9
    • Value of preventing one 5-and-over death from malaria: 83.1
    • Value of preventing one under-5 death from vitamin A deficiency: 118.4
    • Value of averting one stillbirth (1 month before birth): 33.4
    • Value of averting one neonatal death from syphilis: 84
    • Value of averting one year of life lived with disease/disability (YLD): 2.3

     

  5. ^

     See calculations here.

  6. ^

     Source here.

  7. ^

     Source here.

  8. ^

     These figures are based on this lightly vetted spreadsheet comparing IHME and IGME malaria mortality estimates and how incorporating IGME figures would affect our malaria mortality estimates.

  9. ^

     Source here. Filters need to be set to [World - Nigeria - 2020 - Maternal deaths]

  10. ^

     Source: Institute for Health Metrics and Evaluation (IHME). Used with permission. All rights reserved

  11. ^

     For more details, see the “Indirect malaria mortality” section of our report on ITNs, the

    “Non-malaria deaths indirectly averted” section of our report on SMC, and the “Adjustment for all-cause mortality effect” section of our report on New Incentives.

  12. ^

     From our ITNs intervention report:

    Our estimate of 0.75 is based on triangulating three different sources of information:

    Our analysis of the relationship between all-cause mortality and malaria incidence in Pryce et al. implies a value of up to 1.5 indirect deaths for every direct malaria death.221 Our best guess is that this is an overestimate, because:

    The studies underlying the Pryce et al. meta-analysis took place in the 1980s, 1990s, and 2000s.222 It is plausible that the ratio of direct to indirect deaths has fallen since that time in malaria-endemic countries as overall health has improved and under-five mortality has decreased.223

    We use national-level estimates from the Global Burden of Disease project from the countries where the studies in Pryce et al. were conducted as inputs to our analysis (see here). Intuitively, we might expect the Pryce et al. RCTs to be conducted in areas where malaria mortality was higher than the national average. If that assumption is correct, our analysis would be likely to overestimate the share of indirect deaths and underestimate the share of direct malaria deaths.

    We have also spoken with malaria experts who told us that it is widely accepted there are roughly 0.5 to 1 indirect malaria deaths for every direct malaria death.224

    Our analysis of water chlorination programs, another intervention that reduces child mortality by averting infectious diseases, suggests a ratio of 2.7 deaths indirectly averted for every death directly averted from enteric infection.225 This leads us to believe that a high ratio of indirect to direct deaths is plausible.

    Our analysis of the relationship between all-cause mortality and malaria incidence in Pryce et al. implies a value of up to 1.5 indirect deaths for every direct malaria death.221 Our best guess is that this is an overestimate, because:

    The studies underlying the Pryce et al. meta-analysis took place in the 1980s, 1990s, and 2000s.222 It is plausible that the ratio of direct to indirect deaths has fallen since that time in malaria-endemic countries as overall health has improved and under-five mortality has decreased.223

    We use national-level estimates from the Global Burden of Disease project from the countries where the studies in Pryce et al. were conducted as inputs to our analysis (see here). Intuitively, we might expect the Pryce et al. RCTs to be conducted in areas where malaria mortality was higher than the national average. If that assumption is correct, our analysis would be likely to overestimate the share of indirect deaths and underestimate the share of direct malaria deaths.

    We have also spoken with malaria experts who told us that it is widely accepted there are roughly 0.5 to 1 indirect malaria deaths for every direct malaria death.224

    Our analysis of water chlorination programs, another intervention that reduces child mortality by averting infectious diseases, suggests a ratio of 2.7 deaths indirectly averted for every death directly averted from enteric infection.225 This leads us to believe that a high ratio of indirect to direct deaths is plausible.

    Our analysis of the relationship between all-cause mortality and malaria incidence in Pryce et al. implies a value of up to 1.5 indirect deaths for every direct malaria death.221 Our best guess is that this is an overestimate, because:

    The studies underlying the Pryce et al. meta-analysis took place in the 1980s, 1990s, and 2000s.222 It is plausible that the ratio of direct to indirect deaths has fallen since that time in malaria-endemic countries as overall health has improved and under-five mortality has decreased.223

    We use national-level estimates from the Global Burden of Disease project from the countries where the studies in Pryce et al. were conducted as inputs to our analysis (see here). Intuitively, we might expect the Pryce et al. RCTs to be conducted in areas where malaria mortality was higher than the national average. If that assumption is correct, our analysis would be likely to overestimate the share of indirect deaths and underestimate the share of direct malaria deaths.

    We have also spoken with malaria experts who told us that it is widely accepted there are roughly 0.5 to 1 indirect malaria deaths for every direct malaria death.224

    Our analysis of water chlorination programs, another intervention that reduces child mortality by averting infectious diseases, suggests a ratio of 2.7 deaths indirectly averted for every death directly averted from enteric infection.225 This leads us to believe that a high ratio of indirect to direct deaths is plausible.

Show all footnotes
Comments1


Sorted by Click to highlight new comments since:

Executive summary: GiveWell is seeking external research assistance on several key questions that could improve their grantmaking decisions, including red teaming newer program areas, validating moral weights assumptions, and reconciling conflicting disease burden data sources.

Key points:

  1. Priority research areas include scrutinizing newer grantmaking programs like chlorination, malnutrition, and tuberculosis management through "red teaming" analysis.
  2. Need to validate moral weights assumptions by comparing with recent VSL studies from low/middle-income countries and gathering evidence on morbidity vs. consumption trade-offs.
  3. Critical need to reconcile conflicting disease burden estimates between IHME and other sources (UN IGME, WHO, MMEIG) which could significantly impact funding decisions.
  4. Important to determine accurate ratios of indirect to direct deaths across different health interventions, as current assumptions vary widely (0.75-5x) without strong empirical backing.
  5. Actionable request: Researchers are invited to investigate these questions and post findings to the forum; interested parties should consider applying for Senior Researcher role.

 

 

This comment was auto-generated by the EA Forum Team. Feel free to point out issues with this summary by replying to the comment, and contact us if you have feedback.

Curated and popular this week
Paul Present
 ·  · 28m read
 · 
Note: I am not a malaria expert. This is my best-faith attempt at answering a question that was bothering me, but this field is a large and complex field, and I’ve almost certainly misunderstood something somewhere along the way. Summary While the world made incredible progress in reducing malaria cases from 2000 to 2015, the past 10 years have seen malaria cases stop declining and start rising. I investigated potential reasons behind this increase through reading the existing literature and looking at publicly available data, and I identified three key factors explaining the rise: 1. Population Growth: Africa's population has increased by approximately 75% since 2000. This alone explains most of the increase in absolute case numbers, while cases per capita have remained relatively flat since 2015. 2. Stagnant Funding: After rapid growth starting in 2000, funding for malaria prevention plateaued around 2010. 3. Insecticide Resistance: Mosquitoes have become increasingly resistant to the insecticides used in bednets over the past 20 years. This has made older models of bednets less effective, although they still have some effect. Newer models of bednets developed in response to insecticide resistance are more effective but still not widely deployed.  I very crudely estimate that without any of these factors, there would be 55% fewer malaria cases in the world than what we see today. I think all three of these factors are roughly equally important in explaining the difference.  Alternative explanations like removal of PFAS, climate change, or invasive mosquito species don't appear to be major contributors.  Overall this investigation made me more convinced that bednets are an effective global health intervention.  Introduction In 2015, malaria rates were down, and EAs were celebrating. Giving What We Can posted this incredible gif showing the decrease in malaria cases across Africa since 2000: Giving What We Can said that > The reduction in malaria has be
Rory Fenton
 ·  · 6m read
 · 
Cross-posted from my blog. Contrary to my carefully crafted brand as a weak nerd, I go to a local CrossFit gym a few times a week. Every year, the gym raises funds for a scholarship for teens from lower-income families to attend their summer camp program. I don’t know how many Crossfit-interested low-income teens there are in my small town, but I’ll guess there are perhaps 2 of them who would benefit from the scholarship. After all, CrossFit is pretty niche, and the town is small. Helping youngsters get swole in the Pacific Northwest is not exactly as cost-effective as preventing malaria in Malawi. But I notice I feel drawn to supporting the scholarship anyway. Every time it pops in my head I think, “My money could fully solve this problem”. The camp only costs a few hundred dollars per kid and if there are just 2 kids who need support, I could give $500 and there would no longer be teenagers in my town who want to go to a CrossFit summer camp but can’t. Thanks to me, the hero, this problem would be entirely solved. 100%. That is not how most nonprofit work feels to me. You are only ever making small dents in important problems I want to work on big problems. Global poverty. Malaria. Everyone not suddenly dying. But if I’m honest, what I really want is to solve those problems. Me, personally, solve them. This is a continued source of frustration and sadness because I absolutely cannot solve those problems. Consider what else my $500 CrossFit scholarship might do: * I want to save lives, and USAID suddenly stops giving $7 billion a year to PEPFAR. So I give $500 to the Rapid Response Fund. My donation solves 0.000001% of the problem and I feel like I have failed. * I want to solve climate change, and getting to net zero will require stopping or removing emissions of 1,500 billion tons of carbon dioxide. I give $500 to a policy nonprofit that reduces emissions, in expectation, by 50 tons. My donation solves 0.000000003% of the problem and I feel like I have f
 ·  · 8m read
 · 
In my past year as a grantmaker in the global health and wellbeing (GHW) meta space at Open Philanthropy, I've identified some exciting ideas that could fill existing gaps. While these initiatives have significant potential, they require more active development and support to move forward.  The ideas I think could have the highest impact are:  1. Government placements/secondments in key GHW areas (e.g. international development), and 2. Expanded (ultra) high-net-worth ([U]HNW) advising Each of these ideas needs a very specific type of leadership and/or structure. More accessible options I’m excited about — particularly for students or recent graduates — could involve virtual GHW courses or action-focused student groups.  I can’t commit to supporting any particular project based on these ideas ahead of time, because the likelihood of success would heavily depend on details (including the people leading the project). Still, I thought it would be helpful to articulate a few of the ideas I’ve been considering.  I’d love to hear your thoughts, both on these ideas and any other gaps you see in the space! Introduction I’m Mel, a Senior Program Associate at Open Philanthropy, where I lead grantmaking for the Effective Giving and Careers program[1] (you can read more about the program and our current strategy here). Throughout my time in this role, I’ve encountered great ideas, but have also noticed gaps in the space. This post shares a list of projects I’d like to see pursued, and would potentially want to support. These ideas are drawn from existing efforts in other areas (e.g., projects supported by our GCRCB team), suggestions from conversations and materials I’ve engaged with, and my general intuition. They aren’t meant to be a definitive roadmap, but rather a starting point for discussion. At the moment, I don’t have capacity to more actively explore these ideas and find the right founders for related projects. That may change, but for now, I’m interested in